25
Mar

Harvard professor Doug Melton is having quite a week. His work on potential cell therapies for diabetes just fueled the launch of a well-funded biotech startup, and now he’s signed up with AstraZeneca to help the drugmaker spotlight new treatments for the disease.

…read more

Source: AstraZeneca buys into Harvard’s stem cell tech for diabetes R&D

    

0 No comments